634 research outputs found

    Vaccinate: Posters from the COVID-19 Pandemic

    Get PDF
    In 2022 we are living through a global pandemic, and vaccines are one of the most effective strategies for slowing the spread of infectious disease, minimizing symptoms, and lowering healthcare demands. In short, vaccines save lives and can reduce the risk of contagion from social interaction. In the United States in late 2021, after the vaccines had been broadly available for almost a year, one in five adults still chose not to get vaccinated against COVID-19. Art can disrupt what is embedded in our minds and open us up to new perspectives and insights. We hope to offer access to images, insights, and knowledge that help people have the freedom to consider their role in the pandemic and the role of vaccines. We hope that experiencing the creativity, humor, and sentiments of artists will encourage those who have avoided the COVID-19 vaccine to reconsider and take advantage of a way to prepare their immune system should they be exposed to the virus. We are thrilled to provide the posters for those who want to enjoy, reflect, and share them with others who are inspired by the power of vaccines and who want to help stop the spread of deadly viruses. CONTRIBUTING ARTISTS include: Rachel Claire Balter, Thane Benson, Randy Bish, Katie Bradshaw, Heinzy Cruz, Hector Curriel, Ben Darling, Nicholas Deason, Kerry Eddy, Margaret Elsener, Paul Fell, David L. Felley, Bob Hall, Hayley Jurek, Justin Kemerling, Abbey Krienke, Stephen Lahey, Anna Lindstrom, Malia McCreight, Yihang Meng, Eric Morris, Katie Nieland, Henry Payer, Natalie Pulte, Nikolaus Stevenson, Pawl Tisdale, Janet Walters, William Wells, & Jave Yoshimoto DOI:10.32873/unl.dc.zea.1334https://digitalcommons.unl.edu/zeabook/1132/thumbnail.jp

    Inhibitory Effects of ab initio Antiviral Peptides Efficiently Designed Based on APD3 Database

    Get PDF
    Natural antimicrobial peptides (AMPs) aid in many organisms innate immune defense against pathogens. Engineering new therapeutics from natural AMP templates may provide an effective treatment to emerging microbial infections such as SARS-CoV-2, Ebola viruses, and drug-resistant bacteria. One way to design antimicrobial peptides is the database filtering technology (DFT). The DFT is an ab initio design that selects the most probable parameters for an AMP by statistical analysis in the antimicrobial peptide database (https://aps.unmc.edu). To our knowledge, the DFT design has never been used to develop an antiviral peptide. We present here the improved DFT that enables a faster and more efficient design. Indeed, the peptide designed in this manner inhibits both SARS-CoV-2 and Ebola viruses. We also validated that deviations from the most probable length or amino acids led to a decrease in peptide activity. Further refinement of the peptide by introducing a disulfide bond improved peptide stability to proteases such as chymotrypsin and trypsin. Our database designed and improved peptide 1 (DDIP1) has the potential as a novel antiviral agent.https://digitalcommons.unmc.edu/surp2021/1033/thumbnail.jp

    Improved Database Filtering Technology Enables More Efficient Ab Initio Design of Potent Peptides against Ebola Viruses

    Get PDF
    The rapid mutations of viruses such as SARS-CoV-2 require vaccine updates and the development of novel antiviral drugs. This article presents an improved database filtering technology for a more effective design of novel antiviral agents. Different from the previous approach, where the most probable parameters were obtained stepwise from the antimicrobial peptide database, we found it possible to accelerate the design process by deriving multiple parameters in a single step during the peptide amino acid analysis. The resulting peptide DFTavP1 displays the ability to inhibit Ebola virus. A deviation from the most probable peptide parameters reduces antiviral activity. The designed peptides appear to block viral entry. In addition, the amino acid signature provides a clue to peptide engineering to gain cell selectivity. Like human cathelicidin LL-37, our engineered peptide DDIP1 inhibits both Ebola and SARS-CoV-2 viruses. These peptides, with broad antiviral activity, may selectively disrupt viral envelopes and offer the lasting efficacy required to treat various RNA viruses, including their emerging mutants

    Aerosol and Surface Contamination of SARS-CoV-2 Observed in Quarantine and Isolation Care

    Get PDF
    The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated in Wuhan, China in late 2019, and its resulting coronavirus disease, COVID-19, was declared a pandemic by the World Health Organization on March 11, 2020. The rapid global spread of COVID-19 represents perhaps the most significant public health emergency in a century. As the pandemic progressed, a continued paucity of evidence on routes of SARS-CoV-2 transmission has resulted in shifting infection prevention and control guidelines between classically-defined airborne and droplet precautions. During the initial isolation of 13 individuals with COVID-19 at the University of Nebraska Medical Center, we collected air and surface samples to examine viral shedding from isolated individuals. We detected viral contamination among all samples, supporting the use of airborne isolation precautions when caring for COVID-19 patients

    The Size and Culturability of Patient-Generated SARS-CoV-2 Aerosol

    Get PDF
    BACKGROUND: Aerosol transmission of COVID-19 is the subject of ongoing policy debate. Characterizing aerosol produced by people with COVID-19 is critical to understanding the role of aerosols in transmission. OBJECTIVE: We investigated the presence of virus in size-fractioned aerosols from six COVID-19 patients admitted into mixed acuity wards in April of 2020. METHODS: Size-fractionated aerosol samples and aerosol size distributions were collected from COVID-19 positive patients. Aerosol samples were analyzed for viral RNA, positive samples were cultured in Vero E6 cells. Serial RT-PCR of cells indicated samples where viral replication was likely occurring. Viral presence was also investigated by western blot and transmission electron microscopy (TEM). RESULTS: SARS-CoV-2 RNA was detected by rRT-PCR in all samples. Three samples confidently indicated the presence of viral replication, all of which were from collected sub-micron aerosol. Western blot indicated the presence of viral proteins in all but one of these samples, and intact virions were observed by TEM in one sample. SIGNIFICANCE: Observations of viral replication in the culture of submicron aerosol samples provides additional evidence that airborne transmission of COVID-19 is possible. These results support the use of efficient respiratory protection in both healthcare and by the public to limit transmission

    Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein

    Get PDF
    The new coronavirus, SARS-CoV-2, transmits rapidly from human-to-human resulting in the ongoing pandemic. SARS-CoV-2 infects angiotensin-converting enzyme 2 (ACE-2) expressing lung, heart, kidney, intestine, gall bladder, and testicular tissues of patients, leading to organ failure and sometimes death.1, 2 Currently, COVID-19 patients are treated with different agents, including favilavir, remdesivir, chloroquine, hydroxychloroquine, lopinavir, darunavir, and tocilizumab.3, 4 However, the safety and efficacy of those drugs against COVID-19 still need further confirmation by randomized clinical trials. Hence, there is an emergent need to repurpose the existing drugs or develop new virus-based and host-based antivirals against SARS-CoV-2. Bromelain is a cysteine protease isolated from pineapple stem and is used as a dietary supplement for treating patients with pain, inflammation,5 thrombosis,6 and cancerPeer Reviewe

    Search for CP violation in D+→ϕπ+ and D+s→K0Sπ+ decays

    Get PDF
    A search for CP violation in D + → ϕπ + decays is performed using data collected in 2011 by the LHCb experiment corresponding to an integrated luminosity of 1.0 fb−1 at a centre of mass energy of 7 TeV. The CP -violating asymmetry is measured to be (−0.04 ± 0.14 ± 0.14)% for candidates with K − K + mass within 20 MeV/c 2 of the ϕ meson mass. A search for a CP -violating asymmetry that varies across the ϕ mass region of the D + → K − K + π + Dalitz plot is also performed, and no evidence for CP violation is found. In addition, the CP asymmetry in the D+s→K0Sπ+ decay is measured to be (0.61 ± 0.83 ± 0.14)%
    • …
    corecore